Complex Parkinsonism (includes pallido-pyramidal syndromes)
Gene: MAPTPMID: 28334843 - new publication providing further evidence. Autophagy-upregulating therapies may be a strategy for the treatment for tauopathies.Created: 14 Aug 2017, 3:26 p.m.
Comment on list classification: Is on the Dementia NGS Panel in the UCLH National Hospital for Neurology and Neurosurgery & Institute of Neurology (NHNN) Neurogenetics genetic testing manual, and consideration of testing for this gene is suggested in the case of familial or unusual syndromes, which may include earlier age of onset: "Complicated parkinsonism such as MSA and PSP generally do not appear to have a high recurrence risk. However, in the case of familial or unusual syndromes, which may include earlier age of onset, consideration to sequence the MAPT gene is suggested. In MSA approximately 10% of patients have a spinocerebellar ataxia (SCA) expansion."Created: 10 Jun 2016, 12:11 p.m.
Publications
Publications for MAPT were set to 28334843
This gene has been classified as Green List (High Evidence).
MAPT was added to Complex Parkinsonism (includes pallido-pyramidal syndromes)panel. Sources: Eligibility statement prior genetic testing
MAPT was added to Complex Parkinsonism (includes pallido-pyramidal syndromes)panel. Sources: UKGTN
Model of inheritance for gene MAPT was changed to MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown
MAPT was added to Complex Parkinsonism (includes pallido-pyramidal syndromes)panel. Sources: Radboud University Medical Center, Nijmegen,Expert
MAPT was added to Complex Parkinsonism (includes pallido-pyramidal syndromes)panel. Sources: Radboud University Medical Center, Nijmegen,Expert